BD (Becton, Dickinson and Company), a leading global medical technology company, today celebrated the grand opening of its newest BD Diagnostics production facility in Mebane, North Carolina. To date, BD has invested $14 million in the 101,000-square-foot facility in Alamance County, which will employ 75 associates, creating 30 new jobs for the County. The new facility provides added manufacturing capacity for diagnostic products that support BD's Women's Health and Cancer strategy.
"BD began operations in Alamance County in 2006 with the acquisition of TriPath Imaging," said Wayne Brinster, VP/GM of Women's Health and Cancer, BD. "Our expansion in Mebane is evidence of our positive experience with the skilled workforce and economic environment here. BD is very pleased to be growing in North Carolina, where we have had operations since 1972, and we appreciate the strong support we have received from the local authorities for this investment."
BD's Women's Health and Cancer platform is committed to developing and providing advanced instruments and reagents to improve disease detection as well as laboratory performance and workflow. The Mebane facility is the second BD Diagnostics plant in North Carolina. The BD facility in Burlington is the largest manufacturing plant for the BD's cervical cancer screening products and also houses management and operation functions. BD is maintaining this facility, where it employs approximately 100 associates.
BD employs approximately 850 associates in North Carolina at four locations: BD Technologies in Research Triangle Park; BD Biosciences in Durham; and BD Diagnostics in Burlington, Research Triangle Park and Mebane. BD is also developing a manufacturing facility in Wilson.
About BD
BD is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to improving people's health throughout the world. BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD's capabilities are instrumental in combating many of the world's most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 29,000 associates in more than 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. For more information, please visit www.bd.com.
This press release may contain certain forward-looking statements (as defined under Federal securities laws) regarding BD's performance, including future revenues, products and income, or events or developments that BD expects to occur or anticipates occurring in the future. All such statements are based upon current expectations of BD and involve a number of business risks and uncertainties. Actual results could vary materially from anticipated results described, implied or projected in any forward-looking statement. Factors that could cause actual results to vary materially from any forward-looking statement include, but are not limited to: competitive factors; pricing and market share pressures; changes in interest or foreign currency exchange rates; difficulties inherent in product development and delays in product introductions; changes in regional, national or foreign economic conditions; increases in energy costs; fluctuations in costs and availability of raw materials and in BD's ability to maintain favorable supplier arrangements and relationships; and changes in healthcare or other governmental regulation; issuance of new or revised accounting standards, as well as other factors discussed in this press release and in BD's filings with the Securities and Exchange Commission. We do not intend to update any forward-looking statements to reflect events or circumstances after the date hereof except as required by applicable laws or regulations.
